Drug Safety Meta-Analysis: Promises and Pitfalls

被引:0
|
作者
Michael A. Stoto
机构
[1] School of Nursing and Health Studies,Department of Health Systems Administration
[2] Georgetown University,undefined
来源
Drug Safety | 2015年 / 38卷
关键词
Major Depressive Disorder; Naproxen; Rosiglitazone; Rofecoxib; Risk Difference;
D O I
暂无
中图分类号
学科分类号
摘要
Meta-analysis has increasingly been used to identify adverse effects of drugs and vaccines, but the results have often been controversial. In one respect, meta-analysis is an especially appropriate tool in these settings. Efficacy studies are often too small to reliably assess risks that become important when a medication is in widespread use, so meta-analysis, which is a statistically efficient way to pool evidence from similar studies, seems like a natural approach. But, as the examples in this paper illustrate, different syntheses can come to qualitatively different conclusions, and the results of any one analysis are usually not as precise as they seem to be. There are three reasons for this: the adverse events of interest are rare, standard meta-analysis methods may not be appropriate for the clinical and methodological heterogeneity that is common in these studies, and adverse effects are not always completely or consistently reported. To address these problems, analysts should explore heterogeneity and use random-effects or more complex statistical methods, and use multiple statistical models to see how dependent the results are to the choice of models.
引用
收藏
页码:233 / 243
页数:10
相关论文
共 50 条
  • [21] Systematic review and meta-analysis: pitfalls of methods
    Lukina, Yu. V.
    Martsevich, S. Yu.
    Kutishenko, N. P.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2016, 12 (02) : 180 - 185
  • [22] The use of meta-analysis in MIS research: Promises and problems
    Hwang, MI
    DATA BASE FOR ADVANCES IN INFORMATION SYSTEMS, 1996, 27 (03): : 35 - 48
  • [23] PROBLEMS AND PROMISES OF META-ANALYSIS IN SPECIAL-EDUCATION
    GUSKIN, SL
    JOURNAL OF SPECIAL EDUCATION, 1984, 18 (01): : 73 - 80
  • [24] Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis
    Sen, Selcuk
    Karahan, Eda
    Buyukulas, Cansu
    Polat, Yasin Onur
    Uresin, Ali Yagiz
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2021, 25 (11): : 753 - +
  • [25] WEIGHT LOSS AND SAFETY OF FOUR APPETITE SUPPRESSANTS DRUG: A META-ANALYSIS
    Farah, D.
    Fonseca, M.
    VALUE IN HEALTH, 2019, 22 : S164 - S164
  • [26] Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis
    Ohlssen, David
    Price, Karen L.
    Xia, H. Amy
    Hong, Hwanhee
    Kerman, Jouni
    Fu, Haoda
    Quartey, George
    Heilmann, Cory R.
    Ma, Haijun
    Carlin, Bradley P.
    PHARMACEUTICAL STATISTICS, 2014, 13 (01) : 55 - 70
  • [27] Safety of drug-eluting stents: demystifying network meta-analysis
    Pocock, Stuart J.
    LANCET, 2007, 370 (9605): : 2099 - 2100
  • [28] Role of Meta-Analysis in Drug Safety: Methodological Considerations and Regulatory Implications
    Hammad, Tarek
    Pinheiro, Simone P.
    Irvine, David
    Kesten, Steven
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S134 - S135
  • [29] Metabolomics and doping analysis: promises and pitfalls
    Botre, Francesco
    Georgakopoulos, Costas
    Elrayess, Mohamed A.
    BIOANALYSIS, 2020, 12 (11) : 719 - 722
  • [30] Drug-induced Death of Eosinophils Promises and Pitfalls
    Persson, Carl
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (06) : 605 - 606